DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Grows Stake in BioNTech SE (NASDAQ:BNTX)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 632.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 501,897 shares of the company's stock after purchasing an additional 433,388 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned 0.21% of BioNTech worth $57,191,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BNTX. SG Americas Securities LLC lifted its holdings in shares of BioNTech by 412.3% during the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock worth $4,726,000 after acquiring an additional 33,375 shares during the last quarter. Mirabaud & Cie SA purchased a new position in BioNTech during the fourth quarter valued at $684,000. Bank of New York Mellon Corp grew its position in BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after purchasing an additional 150 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of BioNTech during the fourth quarter valued at approximately $1,118,000. Finally, Van ECK Associates Corp increased its holdings in shares of BioNTech by 25.1% in the 4th quarter. Van ECK Associates Corp now owns 118,418 shares of the company's stock worth $13,493,000 after purchasing an additional 23,733 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on BNTX. Citigroup reaffirmed a "buy" rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Morgan Stanley lowered their price objective on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. HC Wainwright reduced their price target on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, BMO Capital Markets increased their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and an average target price of $142.73.

BioNTech Stock Performance

Shares of BioNTech stock traded down $2.77 on Tuesday, reaching $94.50. 778,350 shares of the stock were exchanged, compared to its average volume of 922,318. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $98.44 and a two-hundred day moving average price of $109.39. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The firm has a market capitalization of $22.68 billion, a price-to-earnings ratio of -45.00 and a beta of 1.35.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. The company's revenue was down 19.5% compared to the same quarter last year. Analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.